# Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

> **NCT06315738** · PHASE1,PHASE2 · RECRUITING · sponsor: **Noveome Biotherapeutics, formerly Stemnion** · enrollment: 36 (estimated)

## Conditions studied

- Necrotizing Enterocolitis

## Interventions

- **BIOLOGICAL:** ST266

## Key facts

- **NCT ID:** NCT06315738
- **Lead sponsor:** Noveome Biotherapeutics, formerly Stemnion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2029-06
- **Final completion:** 2029-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06315738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06315738, "Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06315738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*